Infinite Epigenetics Acquires Tally Health

Taconic Biosciences Acquires TransCure bioServices

January 20, 2026

Biotechnology

Taconic Biosciences has acquired TransCure bioServices SAS to create an integrated global translational research platform combining Taconic's genetically engineered and humanized mouse models with TransCure's preclinical in vivo services. The deal expands Taconic's capabilities across oncology, immunology, infectious disease, and advanced modalities while preserving TransCure's brand and operational structure to ensure continuity for employees and clients.

WIT Acquires Tally Gamification Platform

August 22, 2025

Cloud & SaaS

WIT has acquired the Tally Platform, a real-time audience engagement and gamification technology, to strengthen its digital engagement and data-capture capabilities. As part of the deal Tally CEO Bradley Vettese joins WIT as Chief Growth Strategist, enabling WIT to integrate Tally's real-time features across its global partner network and expand its branded activation offerings.

Epsilogen Acquires TigaTx to Create Pan-Isotype Cancer Antibody Company

April 7, 2025

Biotechnology

Epsilogen Ltd has completed the acquisition of Boston-based TigaTx, Inc., making TigaTx a wholly owned subsidiary. The deal combines TigaTx's engineered IgA antibody assets with Epsilogen's IgE capabilities to build a pan-isotype oncology antibody company and broaden the combined clinical-stage pipeline.

Lantheus Holdings to Acquire Evergreen Theragnostics for $250 Million Upfront

January 28, 2025

Healthcare Services

Lantheus Holdings has signed a definitive agreement to acquire Evergreen Theragnostics in an all-cash deal with a $250 million upfront payment and up to $752.5 million in development and sales milestones. The acquisition is intended to expand Lantheus into a fully integrated radiopharmaceutical leader by adding Evergreen’s radiopharmaceutical CDMO manufacturing infrastructure and development capabilities, as well as the registrational-stage PET diagnostic agent OCTEVY.

OncoCyte Corporation Acquires Insight Genetics

January 10, 2020

Healthcare Services

OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.

H.I.G. Capital Acquires Taconic Biosciences

February 7, 2019

Healthcare Services

H.I.G. Capital, through an affiliate, has completed the acquisition of Taconic Biosciences, a global provider of genetically engineered research models and related services. The private equity investment will partner with Taconic's management to support geographic expansion, broaden product and service offerings, and accelerate M&A-driven growth.